Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles

References

• ToddPAFauldsDOfloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic useDrugs1991428258761723377
   PubMed Web of Science ®Google Scholar
• SaitoASawatariKFukudaYSusceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigsAntimicrob Agents Chemother19852815203862361
   PubMed Web of Science ®Google Scholar
• MonkJPCampoli-RichardsDMOfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic useDrugs1987333463913297617
   PubMed Web of Science ®Google Scholar
• GrünebergRNFelminghamDO’HareMDThe comparative in-vitro activity of ofloxacinJ Antimicrob Chemother198822Suppl C9193182468
   PubMed Web of Science ®Google Scholar
• MartinezMMcDermottPWalkerRPharmacology of the fluoroquinolones: A perspective for the use in domestic animalsVet J2006172102816154368
   PubMed Web of Science ®Google Scholar
• OkonogiSOguchiTYonemochiEPuttipipatkhachornSYamamotoKImproved dissolution of ofloxacin via solid dispersionInt J Pharm1997156175180
   Web of Science ®Google Scholar
• AgroASGarnerETWrightJWde EscobarCVilledaBSeidlinMClinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis mediaClin Ther1998207447599737834
   PubMed Web of Science ®Google Scholar
• GentryLORodriguez-GomezGOfloxacin versus parenteral therapy for chronic osteomyelitisAntimicrob Agents Chemother1991355385412039205
   PubMed Web of Science ®Google Scholar
• WangFGuXJZhangMFTaiTYTreatment of typhoid fever with ofloxacinJ Antimicrob Chemother1989237857882759925
   PubMed Web of Science ®Google Scholar
• MarierJFDucharmeMPDiMarcoMTwo open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediateand extended-release formulations in healthy subjectsClin Ther2006282070208017296463
   PubMed Web of Science ®Google Scholar
• YewWWKwanSYMaWKKhinMAChanPYIn-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosisJ Antimicrob Chemother1990262272362120177
   PubMed Web of Science ®Google Scholar
• ChavanpatilMJainPChaudhariSShearRVaviaPDevelopment of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluationInt J Pharm200530417818416198522
   PubMed Web of Science ®Google Scholar
• CuiYZhangYTangXIn vitro and in vivo evaluation of ofloxacin sustained release pelletsInt J Pharm2008360475218538518
   PubMed Web of Science ®Google Scholar
• ChavanpatilMDJainPChaudhariSShearRVaviaPRNovel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacinInt J Pharm2006316869216567072
   PubMed Web of Science ®Google Scholar
• FurneriPMFrestaMPuglisiGTemperaGOfloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteriaAntimicrob Agents Chemother2000442458246410952595
   PubMed Web of Science ®Google Scholar
• HwangSMKimDDChungSJShimCKDelivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosisJ Control Release200812910010618538437
   PubMed Web of Science ®Google Scholar
• XieSYWangSLZhaoBKHanCWangMZhouWZEffect of PLGA as a polymeric emulsifer on preparation of hydrophilic protein-loaded solid lipid nanoparticlesColloids Surf B Biointerfaces20086719920418829272
   PubMed Web of Science ®Google Scholar
• MehnertWMäderKSolid lipid nanoparticles: production, characterization and applicationsAdv Drug Deliver Rev200147165196
   PubMed Web of Science ®Google Scholar
• MüllerRHMäderKGohlaSSolid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the artEur J Pharm Biopharm20005016117710840199
   PubMed Web of Science ®Google Scholar
• ZhangZWBuHHGaoZWHuangYGaoFLiYPThe characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in ratsInt J Pharm201039414715320435111
   PubMed Web of Science ®Google Scholar
• MüllerRHRungeSRavelliVMehnertWThunemannAFSoutoEBOral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystalsInt J Pharm2006317828916580159
   PubMed Web of Science ®Google Scholar
• PandeyRSharmaSKhullerGKOral solid lipid nanoparticle-based antitubercular chemotherapyTuberculosis20058541542016256437
   PubMed Web of Science ®Google Scholar
• HanCQiCMZhaoBKHydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studiesJ Vet Pharmacol Ther20093211612319290940
   PubMed Web of Science ®Google Scholar
• WangXFZhangSLZhuLYEnhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivoVet J2011 In press.
   Web of Science ®Google Scholar
• XieSYZhuLYDongZPreparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acidsColloids Surf B Biointerfaces201110.1016/j.colsurfb.2010.12.014
   Web of Science ®Google Scholar
• DeMerlisCCSchonekerDRReview of the oral toxicity of polyvinyl alcohol (PVA)Food Chem Toxicol20034131932612504164
   PubMed Web of Science ®Google Scholar
• XieSYPanBLWangMFormulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticlesNanomedicine2010569370120662641
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstituteDevelopment of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Standard2nd edClinical and Laboratory Standards InstituteWayne, PA2001
   Google Scholar
• ChakrabortySShuklaDMishraBSinghSLipid – An emerging platform for oral delivery of drugs with poor bioavailabilityEur J Pharm Biopharm20097311519505572
   PubMed Web of Science ®Google Scholar
• LuoYFChenDWRenLXZhaoXLQinJSolid lipid nanoparticles for enhancing vinpocetine’s oral bioavailabilityJ Control Release2006114535916828192
   PubMed Web of Science ®Google Scholar
• MisraRAcharyaSDilnawazFSahooSKSustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(ɛ-caprolactone) nanoparticlesNanomedicine2009551953019572818
   PubMed Web of Science ®Google Scholar
• EsmaeiliFHosseini-NasraMRad-MalekshahiaMSamadiNAtyabiFDinarvandRPreparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticlesNanomedicine2007316116717468055
   PubMed Web of Science ®Google Scholar
• DuchêneDPonchelGBioadhesion of solid oral dosage forms, why and how?Eur J Pharm Biopharm1997441523
   Web of Science ®Google Scholar
• VasirJKTambwekarKGargSBioadhesive microspheres as a controlled drug delivery systemInt J Pharm2003255133212672598
   PubMed Web of Science ®Google Scholar
• Hoogkamp-KorstanjeJAAIn-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infectionsJ Antimicrob Chemother1997404274319338498
   PubMed Web of Science ®Google Scholar
• ZalOO’ReillyTAnimal models in the evaluation of antimicrobial agentsAntimicrob Agents Chemother199135152715311929323
   PubMed Web of Science ®Google Scholar
• CraigWAPharmacokinetic:pharmacodynamic parameters: Rationale for antibacterial dosing of mice and menClin Infect Dis1998261129455502
   PubMed Web of Science ®Google Scholar
• FuKPLafredoSCFolenoBIn vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacinAntimicrob Agents Chemother1992368608661503449
   PubMed Web of Science ®Google Scholar
• LodeHBornerKKoeppePPharmacodynamics of fluoroquinolonesClin Infect Dis19982733399675446
   PubMed Web of Science ®Google Scholar
• WiseRLockleyMRThe pharmacokinetics of ofloxacin and a review of its tissue penetrationJ Antimicrob Chemother198822Suppl C59643182463
   PubMed Web of Science ®Google Scholar
• HowardBMAPinneyRJSmithJTPost-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcusaureus, and Streptococcus pyogenesChemotherapy1993392652718325128
   PubMed Web of Science ®Google Scholar